Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 23.4% | 28.0% | 15.0% | 21.1% | 46.0% | 87.8% | 29.7% | 33.4% | 17.0% | 17.9% | 13.4% | 11.1% | 29.3% | 6.9% | 65.3% | 12.6% | (20.1%) | 19.0% | 18.9% | 26.5% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is (42.3%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Bristol-Myers Squibb Company have been 3.3% over the past three years, and 3.7% over the past five years.
As of today, Bristol-Myers Squibb Company's Return on Equity (ROE) is (42.3%), which is lower than industry median of 18.5%. It indicates that Bristol-Myers Squibb Company's Return on Equity (ROE) is Bad.